Navigation Links
China Botanic Hosts Technical Exchange for Industry Research Experts

HARBIN, China, Oct. 25, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that the Company has recently hosted a technical exchange between 13 senior research specialists in the field of Traditional Chinese Medicine (TCM) and herbal medicine.

China Botanic participated in the technical exchange with leading research specialists of the TCM industry at the Company's headquarters to review the Company's scientific endeavors. The technical exchange gathering included Mr. Jisheng Chen, a noted medical scholar from the China Academy of Engineering, Mr. Zhengwu Qi, an acclaimed researcher from the China Academy of Sciences, and other well-known scientists and professors specializing in bio-pharmaceutical biological research from China's leading universities and research institutes. Mr. Chen is a pharmaceutical chemist and is renowned for his knowledge of natural medicine chemistry and drug design. Mr. Qi is also a well-known biochemist and a leader in protein and peptide research.  

The leading research specialists recognized the Company's noteworthy achievements in creating effective, plant-based medicines and offered recommendations for further advances. The Company also received suggestions on institutes which may potentially collaborate with China Botanic in researching all-natural plant-based remedies.

"We thank all our distinguished guests for their positive feedback and appreciation of our Siberian Ginseng series and other products," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We believe the technical exchange was a great success and China Botanic's research team benefited from the opportunity to discuss ideas with industry leading experts. The positive review of our products further strengthens our commitment towards becoming a leading global provider of all-natural and plant-based medicines."

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit

Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact:

CCG Investor Relations:China Botanic Pharmaceutical Inc

Mr. Mark Collinson, PartnerMs. Portia Tan, IR Contact

Phone: +1-310-954-1343 (Los Angeles)Tel: 86-451-8260-2162

Email: mark.collinson@ccgir.comEmail:

Website: www.ccgirasia.comMr. Crocker Coulson, PresidentPhone: +1-646-213-1915 (New York)Email:

SOURCE China Botanic Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Medical Technologies Recently Received Approximately 2,200,000 of its ADSs from Two Banks which Borrowed the ADSs in Connection With the Issuance of the Companys Convertible Notes in August 2008
2. Endoscopy Devices Market in Emerging Economies (India, China, Brazil) - Growing Investments in Hospitals to be the Major Growth Driver
3. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
4. WuXi PharmaTech Acquires China-Based Clinical Research Services Companies
5. China Nuvo Solar, Inc. Announces Corporate Name Change to SurgLine International, Inc.
6. Perrigo Expands Infant Formula Distribution in China With Founder Group
7. Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD
8. Boston Scientific Launches Promus Element™ Stent System In China
9. China Botanic Announces Results of Annual General Meeting
10. China Medical Technologies Announces the Approval of the Renewed High and New Technology Enterprise Status for a Major Subsidiary in China
11. China Sky One Medical, Inc. Elects Board Directors at its Annual Shareholders Meeting
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)... WASHINGTON , Nov. 25, 2015  The ... Obstetricians and Gynecologists (ACOG), and the March of ... bipartisan Protecting Our Infants Act of 2015 ... the number of newborns born exposed to drugs, ... Since the bill,s introduction, all three organizations have ...
(Date:11/25/2015)... 25, 2015  Henry Schein, Inc., the world,s largest ... dental, medical and animal health practitioners, will unveil at ... Henry Schein ConnectDental® Pavilion , which brings together for ... solutions designed to help any practice or laboratory enter ... for a schedule of experts appearing at the Pavilion. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s ... STEMI and Sepsis conditions present in similar ways and require time-critical intervention to avoid ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic ... the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 ... need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a ...
Breaking Medicine News(10 mins):